ALAUNOS THERAPEUTICS INC

TCRTNASDAQ

🏆 #3861 by market capEarnings Aug 18US Equity

$843.37▲ $64.77 (+7.68%)

Simulated price

1h—

24h▲ 7.7%

7d—

14d—

30d—

1y—

🏦Market Cap

$5M

Small Cap

📈Revenue Growth (YoY)

-70.0%

Declining

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

952.4x

Expensive

Otter Score

Fair

No chart data available for TCRT.

Trading Snapshot

Day Range: $838.47 – $858.08
52-Week Range: $1.67 – $4.59
Volume: $5.83B
Avg Volume: $5.25B
Shares Outstanding: 2.4M
Next Earnings: Oct 6, 2026

Fundamentals Snapshot

Annual Revenue: $5,000
Last Q Revenue: $1,159
P/E Ratio: —
P/S Ratio: 952.4x
EPS (TTM): $-2.06
Dividend Yield: —

Why Investors Own TCRT

✓High-growth profile — revenue up +57.2% YoY with expanding US Equity exposure.
✓Healthy economics — 56% gross margin and 28% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$5,000▲ +64.5% YoY

Gross Margin (TTM)

55.5%▲ +4.4% YoY

Operating Income (TTM)

$1,615▲ +64.5% YoY

Free Cash Flow (TTM)

$1,380▲ +64.5% YoY

About ALAUNOS THERAPEUTICS INC

Alaunos Therapeutics, Inc. is an oncology company in the clinical trial phase, specializing in the creation of adoptive T-cell receptor (TCR) engineered therapies. Their pipeline includes a TCR Library, currently undergoing Phase I/II clinical trials, which comprises ten T-cell receptors designed to target mutated KRAS, TP53, and EGFR in various cancers such as non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. Additionally, they are advancing hunTR, a platform focused on human neoantigen T-cell receptors, and mbIL-15, intended for solid tumor treatment. The company maintains strategic collaborations, including a licensing agreement with PGEN Therapeutics, Inc., a research and development partnership with The University of Texas MD Anderson Cancer Center, and both a patent licensing and R&D agreement with the National Cancer Institute. Previously known as ZIOPHARM Oncology, Inc., the company adopted its current name, Alaunos Therapeutics, Inc., in January 2022. Its headquarters are located in Houston, Texas.

🦦